HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Clinical trial inclusion, specialist collaboration can improve cancer outcomes for those with HIV
-
- Should individuals with HIV be screened for high-risk HPV infection and anal high-grade squamous intraepithelial lesions?
- Imfinzi improves survival for unresectable non-small cell lung cancer
- Right-to-try legislation: Primum non nocere just went out the window Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Brain PET/MRI: Differentiating between recurrent metastasis and radiation necrosis Munir Ghesani, MD, FACNM; Girish Fatterpekar, MD; Ana M. Franceschi, MD
- Nurse practitioners play an important role in oncology pain, symptom management Brighton Loveday, ANP-BC, AOCNP, ACHPN, APRN
- Biomarkers may predict response to nivolumab for urothelial cancer
- Rivaroxaban reduces risk for venous thromboembolism recurrence among patients with cancer
- Modern therapies minimize recurrence after lumpectomy
-
- Black men may survive longer than white men after chemotherapy for advanced prostate cancer
- Blood test superior to PSA for detecting high-grade prostate cancer
- Blood testing ‘untapped opportunity’ for detection of early-stage lung cancer
- Colorectal cancer treatment costs in US double those for Canada
- Maintenance chemotherapy improves OS in rhabdomyosarcoma
- Crizotinib induces disease control in ALK-positive inflammatory myofibroblastic tumor
- Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma
- Finasteride does not increase risk for prostate cancer death
-
- Genomic marker linked to Lynch syndrome across cancer types
- HemOnc Today honors Next Gen Innovators at ASCO
- Immunotherapy superior to chemotherapy for advanced lung cancer with high tumor mutational burden
- Lisocabtagene maraleucel shows promise for pretreated non-Hodgkin lymphoma
- Maintenance chemotherapy improves OS in rhabdomyosarcoma
- Moxetumomab pasudotox shows promise in relapsed, refractory hairy cell leukemia
- Next-generation sequencing for lung cancer provides substantial cost savings
- Nivolumab confers significant OS benefit in recurrent or metastatic head and neck squamous cell carcinoma
-
- Omega-3 fatty acid use improves symptoms among obese patients with breast cancer
- Palliative care reduces suicide risk among veterans with lung cancer
- Pembrolizumab prolongs survival in recurrent, metastatic head and neck squamous cell carcinoma
- Shorter duration of trastuzumab noninferior for early-stage, HER-2-positive breast cancer
- Taselisib with fulvestrant modestly improves PFS in PIK3CA-mutated breast cancer
- Tumor mutational burden feasible biomarker for benefit from dual checkpoint inhibition
- Upstaging of lung cancer increases with surgery delay
- ‘Striking’ lung cancer data emerge, but uncertainty remains about upfront immuno-oncology combinations
-
- Medicaid expansion improves insurance coverage for cancer survivors
- ‘Room for improvement’ exists in oncologists’ knowledge of medical marijuana
- Erlotinib plus pazopanib shows limited activity, increased toxicity for non-small cell lung cancer
- Venetoclax-rituximab combination improves PFS in refractory chronic lymphocytic leukemia
- Pacritinib reduces splenomegaly, symptoms in myelofibrosis
- Low-fat diet improves breast cancer survival
- Larotrectinib induces durable response in TRK fusion-positive pediatric cancer
- Biomarker predicts prognosis in certain gynecological cancers
-
- Neoadjuvant therapy improves outcomes for locally advanced rectal cancer
- Patients with head and neck cancer more likely to be prescribed opioids
- Married patients more likely to find melanoma earlier
- Updated guidelines lower colorectal cancer screening age to 45 years
- Task force recommendation ‘step toward harmonizing’ prostate cancer screening approaches
- FDA approves Doptelet for thrombocytopenia in adults with chronic liver disease
- FDA approves Yonsa for metastatic castration-resistant prostate cancer
- FDA approves Darzalex for newly diagnosed, transplant-ineligible multiple myeloma
-
- FDA grants fast track designation to Debio 1347 for FGFR-mutated tumors
- FDA approves Retacrit, an Epogen/Procrit biosimilar, for treatment of anemia
- FDA issues alert on decreased survival with pembrolizumab or atezolizumab for urothelial cancer
- FDA approves Tafinlar-Mekinist combination for BRAF-mutated anaplastic thyroid cancer
- FDA grants priority review to cemiplimab for advanced cutaneous squamous cell carcinoma
- FDA grants orphan drug designation to cancer vaccine for rare bone tumor
- FDA grants fast track designation to 5F9 for lymphoma subtypes
- FDA grants priority review to Tecentriq combination for non-small cell lung cancer
-
- Abatacept may reduce graft-versus-host disease after hematopoietic stem cell transplantation
- Breast implant-associated lymphoma more common than originally predicted
- Faster fertility preservation technique did not delay time to breast cancer treatment
- ASCO to honor Stanford oncologist
- Association of American Cancer Institutes to present Distinguished Scientist Award
- Vanderbilt-Ingram Cancer Center names breast cancer research program leader
- 11 institutions join AACR Project GENIE Consortium
- NYU Langone appoints oncological rehabilitation director
-
- Selinexor shows promise for penta-refractory multiple myeloma
- Lonsurf prolongs survival in metastatic gastric cancer
- Addition of pembrolizumab to chemotherapy improves response in metastatic non-small cell lung cancer
- Imbruvica plus Gazyva extends PFS for chronic lymphocytic leukemia